Compared to the IgE isotype control and the corresponding CSPG4 IgG treatment, CSPG4 IgE given either at 7- or 14-day intervals significantly restricted the growth of subcutaneous human melanoma xenografts in mice (Fig. 5c), despite markedly faster clearance of CSPG4 IgE from the circulation compared to CSPG4 IgG (Supplementary Fig. 7c). This evidence concerns the gene IGHE and melanoma.